Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
A trial with no phase registered on ClinicalTrials.gov. The registry status is completed. It enrolled 330 participants.
Also called NCT01516723
- Study
- In this atlas
Overview
- Design
- Interventional study; randomized; single masking; primary purpose treatment
- Phase
- Not applicable
- Enrolled
- 330 participants
- Registry
-
NCT01516723
-
- Started
- (actual)
- Primary completion
- (actual)
- Completion
- (actual)
- Countries
- Belgium, Netherlands
- Registry status
- Completed
Technical summary
Registry record NCT01516723. Randomized; single masking; primary purpose treatment. Start 2012-02 (actual); primary completion 2016-02 (actual). Results not posted.
The registry's words
Labels as the registry gives them, not rewritten.
- Brief title
- Hybrid Sirolimus-eluting Versus Everolimus-eluting Stents for Total Coronary Occlusions
- Acronym
- PRISON-IV
- Condition
- Coronary Artery Disease
- Condition
- Coronary Disease
- Condition
- Coronary Stenosis
- Intervention (Device)
- Hybrid sirolimus- and everolimus-eluting stents (ORSIRO, XIENCE PRIME)
- Lead sponsor
- R&D Cardiologie
- Collaborator
- Biotronik SE & Co. KG
Record details
- Record id
cardio:ct-nct01516723- Content hash
d99d1901c700ec60cea53cfb5edf5d235a1948002aa9dca4fd88a05226cb6a7a